We're excited to announce that our partner, Innovent Biologics, presented encouraging Phase 2 clinical results for IBI302—a dual-targeted anti-VEGF/complement therapy for neovascular age-related macular degeneration (nAMD)—at the AAO 2024 Annual Meeting. The data demonstrated comparable efficacy to Aflibercept, with reduced central subfield thickness and potential for extended dosing intervals. The Phase 3 trial is now underway, offering hope for an advanced treatment option in nAMD.
For further information, please visit here.
*AAO, American Academy of Ophthalmology
*IBI302 is a first-in-class dual-target therapeutic protein for treating neovascular age-related macular degeneration (nAMD). It inhibits VEGF to block angiogenesis and suppresses complement activation, addressing both vascular and immune pathways to control inflammation and disease progression.
